245 related articles for article (PubMed ID: 23519388)
1. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.
Schroeder T; Fröbel J; Cadeddu RP; Czibere A; Dienst A; Platzbecker U; Bug G; Uharek L; Fenk R; Germing U; Kröger N; Haas R; Kobbe G
Leukemia; 2013 Sep; 27(9):1910-3. PubMed ID: 23519388
[No Abstract] [Full Text] [Related]
2. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
Schroeder T; Czibere A; Platzbecker U; Bug G; Uharek L; Luft T; Giagounidis A; Zohren F; Bruns I; Wolschke C; Rieger K; Fenk R; Germing U; Haas R; Kröger N; Kobbe G
Leukemia; 2013 Jun; 27(6):1229-35. PubMed ID: 23314834
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
[TBL] [Abstract][Full Text] [Related]
4. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
5. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
Falantes JF; Calderón C; Márquez-Malaver FJ; Aguilar-Guisado M; Martín-Peña A; Martino ML; Montero I; González J; Parody R; Pérez-Simón JA; Espigado I
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):80-6. PubMed ID: 24220615
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
[TBL] [Abstract][Full Text] [Related]
7. Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation.
Yee KW; Brandwein J; Schimmer AD; Gupta V; Del Bel R; Xu W; Minden MD; Schuh AC
Br J Haematol; 2014 Jul; 166(2):303-6. PubMed ID: 24650042
[No Abstract] [Full Text] [Related]
8. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.
Platzbecker U; Wermke M; Radke J; Oelschlaegel U; Seltmann F; Kiani A; Klut IM; Knoth H; Röllig C; Schetelig J; Mohr B; Graehlert X; Ehninger G; Bornhäuser M; Thiede C
Leukemia; 2012 Mar; 26(3):381-9. PubMed ID: 21886171
[TBL] [Abstract][Full Text] [Related]
9. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
Bally C; Thépot S; Quesnel B; Vey N; Dreyfus F; Fadlallah J; Turlure P; de Botton S; Dartigeas C; de Renzis B; Itzykson R; Fenaux P; Adès L
Leuk Res; 2013 Jun; 37(6):637-40. PubMed ID: 23499498
[TBL] [Abstract][Full Text] [Related]
10. Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis.
Drozd-Sokołowska J; Karakulska-Prystupiuk E; Biecek P; Kobylińska K; Piekarska A; Dutka M; Waszczuk-Gajda A; Mądry K; Kopińska A; Gołos A; Góra-Tybor J; Szwedyk P; Bołkun Ł; Czyż A; Giebel S; Basak GW; Dwilewicz-Trojaczek J
Eur J Haematol; 2021 Jul; 107(1):129-136. PubMed ID: 33764578
[TBL] [Abstract][Full Text] [Related]
11. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
12. Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
Claiborne J; Bandyopathyay D; Roberts C; Hawks K; Aziz M; Simmons G; Wiedl C; Chung H; Clark W; McCarty J; Toor A
Leuk Lymphoma; 2019 Nov; 60(11):2733-2743. PubMed ID: 31046498
[TBL] [Abstract][Full Text] [Related]
13. First Steps Towards Successful Post-Transplantation Therapy for Myeloid Malignancies after Allogeneic Blood Stem Cell Transplantation.
Schroeder T; Kobbe G
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1703-4. PubMed ID: 26277403
[No Abstract] [Full Text] [Related]
14. Azacitidine Use After Allogeneic Stem Cell Transplantation-Results From the Polish Adult Leukemia Group.
Drozd-Sokołowska J; Gil L; Waszczuk-Gajda A; Mądry K; Piekarska A; Dutka M; Basak GW; Karakulska-Prystupiuk E; Dwilewicz-Trojaczek J
Transplant Proc; 2016 Jun; 48(5):1802-5. PubMed ID: 27496495
[TBL] [Abstract][Full Text] [Related]
15. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation.
Oran B; Giralt S; Couriel D; Hosing C; Shpall EJ; de Meis E; Khouri IF; Qazilbash M; Anderlini P; Kebriaei P; Popat U; Carrasco-Yalan A; Champlin RE; de Lima M
Leukemia; 2007 Dec; 21(12):2540-4. PubMed ID: 17611563
[No Abstract] [Full Text] [Related]
16. Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies.
Maples KT; Sabo RT; McCarty JM; Toor AA; Hawks KG
Leuk Lymphoma; 2018 Dec; 59(12):2836-2841. PubMed ID: 29616863
[TBL] [Abstract][Full Text] [Related]
17. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).
Ganguly S; Amin M; Divine C; Aljitawi OS; Abhyankar S; McGuirk JP
Ann Hematol; 2013 Apr; 92(4):549-50. PubMed ID: 23111661
[No Abstract] [Full Text] [Related]
18. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.
Lübbert M; Bertz H; Rüter B; Marks R; Claus R; Wäsch R; Finke J
Bone Marrow Transplant; 2009 Nov; 44(9):585-8. PubMed ID: 19363531
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.
Graef T; Kuendgen A; Fenk R; Zohren F; Haas R; Kobbe G
Leuk Res; 2007 Feb; 31(2):257-9. PubMed ID: 16620971
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
